Who Paid My Doc
Leslie Tar
Rheumatology Port Charlotte, FL Medical Doctor
NPI 1720004484 CMS profile 78334
22226 Westchester Blvd, Port Charlotte, FL 33952
General payments
$204
Research payments
$0
Ownership & investment interest
$0
Through program year 2022, Leslie Tar of Port Charlotte, FL is reported in the CMS Open Payments database as having received $204 across 4 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 18th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2022 | General | $72 | 1 | |
| 2021 | General | $28 | 2 | |
| 2019 | General | $103 | 1 |
Beside peers
- Leslie Tar
- Rheumatology median
- Middle half of Rheumatology
- National median
In program year 2025, general payments to Leslie Tar were reported at $0. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.
Show as a table
| Year | Leslie Tar | Rheumatology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $103 | $744 | $153–$2,687 | $163 |
| 2020 | $0 | $462 | $98–$2,027 | $114 |
| 2021 | $28 | $531 | $101–$2,153 | $132 |
| 2022 | $72 | $627 | $125–$2,303 | $149 |
| 2023 | $0 | $741 | $145–$2,524 | $160 |
| 2024 | $0 | $830 | $166–$2,660 | $164 |
| 2025 | $0 | $903 | $171–$2,775 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 57 drugsPart D claims
4,135
Drug cost
$1,560,665
Branded share of claims
24.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 | Brand | 66 | $319,536 | |
| Orencia Abatacept/Maltose | Brand | 69 | $294,016 | |
| Remicade Infliximab | Brand | 30 | $230,914 | |
| Humira(Cf) Pen Adalimumab | Brand | 25 | $168,337 | |
| Xolair Omalizumab | Brand | 55 | $115,462 | |
| Prolia Denosumab | Brand | 48 | $83,920 | |
| Actemra Tocilizumab | Brand | 41 | $74,660 | |
| Orencia Abatacept | Brand | 12 | $66,799 | |
| Otezla Apremilast | Brand | 13 | $62,499 | |
| Renflexis Infliximab-Abda | Brand | 14 | $45,915 |
The 10 drugs with the highest cost, of 57 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 49 billing codesPaid by Medicare
$3,807,940
Medicare patients
567
Services billed
253,800
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Depression | 75% | |
| Arthritis | 75% | |
| Osteoporosis | 42% | |
| Ischemic heart disease | 41% | |
| COPD | 33% | |
| Chronic kidney disease | 31% | |
| Diabetes | 28% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0129 | Office | 60 | 36,750 | $1,244,403 |
| Injection, tocilizumab, 1 mg J3262 | Office | 33 | 101,560 | $478,124 |
| Injection, omalizumab, 5 mg J2357 | Office | 25 | 10,860 | $324,554 |
| Injection, denosumab, 1 mg J0897 | Office | 101 | 9,960 | $205,114 |
| Injection, infliximab, excludes biosimilar, 10 mg J1745 | Office | 30 | 8,040 | $200,561 |
| Injection, golimumab, 1 mg, for intravenous use J1602 | Office | 11 | 8,150 | $74,203 |
| Injection, methylprednisolone sodium succinate, 5 mg J2919 | Office | 130 | 22,850 | $5,198 |
| Injection, methylprednisolone sodium succinate, up to 125 mg J2930 | Office | 106 | 264 | $1,194 |
| Injection, diphenhydramine hcl, up to 50 mg J1200 | Office | 137 | 1,223 | $791 |
| Infusion, normal saline solution, 250 cc J7050 | Office | 123 | 1,011 | $522 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
4 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Rheumatology in Florida
Related records
Rheumatology in Florida
Practitioners in the same specialty and state, ranked by reported value.
All Rheumatology
Everyone recorded under this specialty, nationwide.
Doctors in Florida
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.